Pfizer inks $2.6bn autoimmune deal with China’s Starna for CAR-T therapies
Pfizer is securing ex-China rights to three in vivo CAR-T programmes that are at the pre-IND stage.
Pfizer is securing ex-China rights to three in vivo CAR-T programmes that are at the pre-IND stage.